Title
Subscribe to the Magazine for free
Subscribe for free to keep reading! If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

What Happens When Drug-Induced Lupus is Left Untreated?

Written By

Why This Was Updated?

Our specialists regularly review advancements in health and wellness, ensuring our articles are updated with the newest information as it becomes accessible.
Medically Reviewed by
Dr.
Ayesha Bryant
MSPH, MD

Drug-induced lupus is a condition that can develop as a side effect of certain medications. While it typically mimics symptoms of systemic lupus erythematosus (SLE), a more common form of lupus, DIL is often temporary and resolves once the medication is discontinued. 

However, if not addressed, it may contribute to symptoms like joint pain, fatigue, and muscle aches, which could impact daily life. Recognizing the signs and seeking timely care is crucial to managing its impact on overall health.

[signup]

Understanding Drug-Induced Lupus

Drug-induced lupus is a condition where certain medications may trigger the body's immune system to attack its own cells, potentially leading to inflammation and lupus-like symptoms. Unlike the autoimmune-driven lupus seen in SLE, DIL is typically linked directly to medication use, and it generally resolves when the offending drug is stopped. 

Causes and Risk Factors

Certain drugs, like hydralazine and procainamide, used to treat high blood pressure and manage irregular heartbeats, respectively, are known to be linked with DIL. Other drugs linked to DIL include various antibiotics, such as minocycline, often used to treat acne or bacterial infections. 

While these antibiotics are generally well-tolerated, they can trigger lupus-like symptoms in some individuals. Anti-seizure medications, such as phenytoin and carbamazepine, which are used to manage epilepsy and other seizure disorders, have also been reported to cause DIL.

Additionally, some biologics and immunosuppressants, particularly those used to treat autoimmune diseases like rheumatoid arthritis or certain cancers, may contribute to the development of DIL. 

Prolonged use of drugs that are associated with DIL may increase the risk, as the body has more time to react to the medication and possibly develop lupus-like symptoms. Typically, the symptoms of DIL arise after months or even years of continuous use of the medication, which is why long-term users are more closely monitored.

Genetic susceptibility plays a significant role; certain genetic markers or family histories of autoimmune diseases may predispose a person to develop lupus-like symptoms when exposed to triggering medications. 

For example, individuals with specific genetic variants affecting their immune system functions may have a higher risk of developing DIL.

Additionally, immune system characteristics and the body's overall response to inflammation are important. People who already have immune system irregularities, such as those with pre-existing autoimmune conditions, may be more susceptible to developing DIL. 

Symptoms and Diagnosis

The symptoms of drug-induced lupus often appear after someone has started a new medication. Common signs include joint pain, muscle aches, fever, and a rash that may resemble that seen in systemic lupus. 

A healthcare provider will review the individual’s medical history, current medication use, and timing of symptom onset. Blood tests may be used to detect specific markers, like antibodies, that are commonly associated with DIL. This can help healthcare providers differentiate it from other forms of lupus and autoimmune diseases.

Examples of tests that may help with diagnosis include:

Risks of Untreated Drug-Induced Lupus

If drug-induced lupus (DIL) is not managed, it may cause more than just temporary discomfort. While symptoms often start mild, they may worsen and lead to complications affecting physical and mental well-being. Understanding these risks helps highlight the importance of proper management.

Progression of Symptoms

While drug-induced lupus is generally less severe than other types of lupus, leaving it untreated can lead to a progression of symptoms and potential complications. Symptoms that start as mild—such as joint pain and fatigue—may become more intense if not managed promptly. 

In rare cases, issues like kidney inflammation (lupus nephritis) or serositis (inflammation of the tissues surrounding organs) could develop, potentially requiring additional medical care. 

Long-Term Health Implications

While DIL often tends to be milder than Systemic Lupus Erythematosus (SLE), leaving it untreated can still lead to complications. These may include:

  • Prolonged Joint and Muscle Pain: Persistent pain can interfere with mobility and make daily tasks more difficult, impacting overall quality of life.
  • Skin Rashes: Rashes associated with DIL may spread or worsen without proper management.
  • Possible Inflammation: In rare cases, unmanaged DIL could contribute to inflammation involving the heart (pericarditis) or lungs (pleuritis), which may cause discomfort or other health concerns. 

Psychological and Social Effects

Living with chronic symptoms such as pain, fatigue, and rashes may contribute to anxiety, depression, or stress. Socially, individuals might find it difficult to maintain work, engage in social activities, or keep up with daily routines, potentially leading to feelings of isolation or helplessness.

Delay in Resolving Symptoms

A specific medication often triggers DIL symptoms. If the medication causing these symptoms is not identified and adjusted, relief may be delayed. Early identification and management may help symptoms resolve more quickly.

Importance of Early Detection and Management

Identifying and addressing drug-induced lupus (DIL) early can make a significant difference in outcomes. With prompt action, symptoms can be managed effectively, and the chances of complications can be greatly reduced.

Benefits of Timely Treatment

Timely treatment is important for helping to prevent symptoms from worsening. In most cases, stopping the triggering medication can improve symptoms within weeks or months. Healthcare professionals may recommend supportive treatments like anti-inflammatory medications to ease joint pain and fatigue or corticosteroids to manage more severe inflammation if symptoms persist.

Management Strategies

Healthcare providers play an essential role in monitoring symptoms and adjusting medications. They also guide patients in recognizing early warning signs of DIL and understanding when a medication review is necessary. Proper management and medical follow-up can help individuals achieve recovery and reduce the risk of long-term damage.

Managing Drug-Induced Lupus with a Healthcare Provider

Proper management of drug-induced lupus (DIL) requires close collaboration with healthcare professionals. This partnership is essential for identifying symptoms, ensuring an accurate diagnosis, and creating a safe and effective treatment plan to address and resolve the condition. Here’s how working with a healthcare provider can help you manage DIL effectively.

Collaboration with Healthcare Professionals

When symptoms of DIL appear, such as joint pain, muscle aches, fever, or skin rashes, it’s important to contact a healthcare provider. They play a critical role in ensuring an accurate diagnosis by:

  • Evaluating Symptoms and Medical History: A healthcare provider will assess your symptoms, medical history, and any medications you are currently taking. This helps to identify any drugs that may be causing DIL.
  • Laboratory Testing: Laboratory Testing: Blood tests may help confirm the presence of certain antibodies (e.g., anti-histone antibodies) commonly associated with DIL and assist in distinguishing it from other autoimmune conditions like SLE.
  • Developing a Treatment Plan: Once DIL is confirmed, your provider will guide you on discontinuing the medication and may offer supportive treatments to manage symptoms as they resolve.

Alternative Medications

If a medication you are taking is identified as the cause of DIL, your provider will help find a safe alternative. This is especially important if the medication is necessary for your overall health and can’t be stopped without a replacement. Key considerations include:

  • Finding Safer Alternatives: Your healthcare provider will evaluate other medications that can be substituted with a lower risk of DIL. For instance, if an antiarrhythmic like procainamide is causing DIL, another heart medication with a different mechanism of action may be considered.
  • Balancing Risks and Benefits: Providers will help weigh the benefits of continuing certain medications against the risks of DIL. If an alternative medication is not an option, the lowest effective dose of the original drug might be maintained while closely monitoring symptoms.

Regular Follow-Ups and Monitoring

Ongoing care is crucial in managing DIL, ensuring that symptoms resolve and no further complications develop. Your healthcare provider may recommend:

  • Regular Appointments: These visits allow your provider to monitor symptom progression and determine how well you recover after stopping the medication. They also provide a chance to address any new or lingering symptoms.
  • Symptom Tracking and Blood Tests: To ensure the DIL improves, you may be asked to keep track of any remaining symptoms or flare-ups. Periodic blood work may be used to check for the resolution of antibodies or inflammation associated with DIL.
  • Adjusting Treatment as Needed: If symptoms don’t resolve as expected or become more severe, your healthcare provider may adjust your treatment plan. This could involve changes in medication or dosages or adding supportive treatments like NSAIDs or corticosteroids to manage inflammation.

[signup]

Key Takeaways

  • Drug-induced lupus (DIL) is a temporary lupus-like condition triggered by certain medications, and stopping the medication usually resolves symptoms.
  • Commonly associated drugs include hydralazine and procainamide, with risk factors being prolonged use and genetic susceptibility.
  • If not managed, DIL may progress from mild symptoms like joint pain and fatigue to more severe concerns, such as kidney inflammation, cardiovascular issues, or serositis.
  • Timely detection and treatment are crucial, as early discontinuation of the offending medication can prevent symptom worsening and reduce long-term health risks.
  • Expert opinions and case studies highlight that managing DIL promptly with medical guidance significantly improves recovery and prevents serious complications.
The information provided is not intended to be a substitute for professional medical advice. Always consult with your doctor or other qualified healthcare provider before taking any dietary supplement or making any changes to your diet or exercise routine.
Learn More
No items found.

Lab Tests in This Article

No lab tests!

Achuff, J. (2024, March 19). The Science of Feeling Older: A Study on Stress and Control in Young Adults. Rupa Health. https://www.rupahealth.com/post/the-science-of-feeling-older-a-study-on-stress-and-control-in-young-adults

ANA Screen by Access Labcorp Draw. (2020). Rupa Health. https://www.rupahealth.com/lab-tests/labcorp-ana-screen

Bryant, A. (2024, September 18). How is Rheumatoid Arthritis Diagnosed? Tests and Procedures. Rupa Health. https://www.rupahealth.com/post/how-is-rheumatoid-arthritis-diagnosed-tests-and-procedures

Chengappa, K. G. (2019). Drug-induced lupus. Indian Journal of Rheumatology, 14(5), 10. https://doi.org/10.4103/0973-3698.272154

Cloyd, J. (2023, March 7). An integrative medicine approach to fatigue. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-fatigue

Fugger, L., Jensen, L. T., & Rossjohn, J. (2020). Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. Cell, 181(1), 63–80. https://doi.org/10.1016/j.cell.2020.03.007

Ghlichloo, I., & Gerriets, V. (2023, May 1). Nonsteroidal Anti-inflammatory Drugs (NSAIDs). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK547742/

He, Y., & Sawalha, A. H. (2018). Drug-induced lupus erythematosus. Current Opinion in Rheumatology, 1. https://doi.org/10.1097/bor.0000000000000522

Hodgens, A., & Sharman, T. (2023). Corticosteroids. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554612/

Hunter, M. P., & Regunath, H. (2020). Pleurisy. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558958/

Justiz Vaillant, A. A., Goyal, A., Bansal, P., & Varacallo, M. (2023, August 4). Systemic Lupus Erythematosus. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK535405/

Katz, U., & Zandman-Goddard, G. (2010). Drug-induced lupus: An update. Autoimmunity Reviews, 10(1), 46–50. https://doi.org/10.1016/j.autrev.2010.07.005

Keyes, E., Grinnell, M., Vazquez, T., Diaz, D., Thomas, P., & Werth, V. P. (2021). Drug-induced subacute cutaneous lupus erythematosus in previously diagnosed systemic lupus erythematosus patients: A case series. JAAD Case Reports, 12, 18–21. https://doi.org/10.1016/j.jdcr.2021.03.048

Khakham, C. (2023, July 21). Integrative and Complementary Approach to Drug-Induced Lupus: Testing, Nutrition, and Supplements. Rupa Health. https://www.rupahealth.com/post/integrative-and-complementary-approach-to-drug-induced-lupus-testing-nutrition-and-supplements

King, G. S., & Hashmi, M. F. (2019). Antiarrhythmic Medications. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482322/

Lee, A. Y. S. (2022). Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus. Immunological Medicine, 1–6. https://doi.org/10.1080/25785826.2022.2060168

McMahon, M., Hahn, B. H., & Skaggs, B. J. (2011). Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Review of Clinical Immunology, 7(2), 227–241. https://doi.org/10.1586/eci.10.98

Moustafa, A. T., Moazzami, M., Engel, L., Bangert, E., Hassanein, M., Marzouk, S., Kravtsenyuk, M., Fung, W., Eder, L., Su, J., Wither, J. E., & Touma, Z. (2020). Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 50(1), 84–94. https://doi.org/10.1016/j.semarthrit.2019.06.017

Musa, R., Brent, L. H., & Qurie, A. (2020). Lupus Nephritis. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499817/

Nazarian, S., & Akhondi, H. (2022). Minocycline. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK554519/

Nevitt, S. J., Marson, A. G., Weston, J., & Tudur Smith, C. (2017). Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001911.pub3

Pretel, M., Marquès, L., & España, A. (2014). Drug-Induced Lupus Erythematosus. Actas Dermo-Sifiliográficas, 105(1), 18–30. https://doi.org/10.1016/j.adengl.2012.09.025

Richardson, B. C. (2019). Drug-Induced Lupus Erythematosus. Elsevier EBooks, 377–388. https://doi.org/10.1016/b978-0-323-47927-1.00031-1

Solhjoo, M., Bansal, P., Goyal, A., & Chauhan, K. (2020). Drug-Induced Lupus Erythematosus. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK441889/

Vaglio, A., Grayson, P. C., Fenaroli, P., Gianfreda, D., Boccaletti, V., Ghiggeri, G. M., & Moroni, G. (2018). Drug-induced lupus: Traditional and new concepts. Autoimmunity Reviews, 17(9), 912–918. https://doi.org/10.1016/j.autrev.2018.03.016

Vaughn, S. E., Kottyan, L. C., Munroe, M. E., & Harley, J. B. (2012). Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. Journal of Leukocyte Biology, 92(3), 577–591. https://doi.org/10.1189/jlb.0212095

Yoshiyuki Kioi, Hideki Yorifuji, Yuichi Higami, & Yoshinori Katada. (2023). Serositis and lymphopenia are common features of systemic lupus erythematosus following SARS‐CoV‐2 infection: A case report and literature review. International Journal of Rheumatic Diseases, 26(11), 2267–2271. https://doi.org/10.1111/1756-185x.14767

Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
See All Magazine Articles
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
National Library of Medicine
Government Authority
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
National Cancer Institute
Government Authority
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
CDC
Government Authority
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
National Institutes of Health
Government Authority
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Brain
Peer Reviewed Journal
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Chest
Peer Reviewed Journal
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source